EX937
Refractory Chronic Cough
Key Facts
About Exxel Pharma
Exxel Pharma is advancing a novel, peripherally-targeted therapeutic platform based on the inhibition of the fatty acid amide hydrolase (FAAH) enzyme to treat conditions driven by neuronal hypersensitivity. Its lead asset, EX937, is poised to enter Phase 1/1b trials for refractory chronic cough, a large market with no FDA-approved therapies. The company's strategy leverages a dual-program approach, with a second set of global FAAH inhibitors targeting central nervous system conditions like Social Anxiety Disorder and Autism Spectrum Disorder. Led by an experienced founder/CEO and a distinguished CSO, Exxel is positioned to address significant unmet needs across multiple high-value neurological and urological indications.
View full company profileAbout Exxel Pharma
Exxel Pharma is advancing a novel, peripherally-targeted therapeutic platform based on the inhibition of the fatty acid amide hydrolase (FAAH) enzyme to treat conditions driven by neuronal hypersensitivity. Its lead asset, EX937, is poised to enter Phase 1/1b trials for refractory chronic cough, a large market with no FDA-approved therapies. The company's strategy leverages a dual-program approach, with a second set of global FAAH inhibitors targeting central nervous system conditions like Social Anxiety Disorder and Autism Spectrum Disorder. Led by an experienced founder/CEO and a distinguished CSO, Exxel is positioned to address significant unmet needs across multiple high-value neurological and urological indications.
View full company profileAbout Exxel Pharma
Exxel Pharma is advancing a novel, peripherally-targeted therapeutic platform based on the inhibition of the fatty acid amide hydrolase (FAAH) enzyme to treat conditions driven by neuronal hypersensitivity. Its lead asset, EX937, is poised to enter Phase 1/1b trials for refractory chronic cough, a large market with no FDA-approved therapies. The company's strategy leverages a dual-program approach, with a second set of global FAAH inhibitors targeting central nervous system conditions like Social Anxiety Disorder and Autism Spectrum Disorder. Led by an experienced founder/CEO and a distinguished CSO, Exxel is positioned to address significant unmet needs across multiple high-value neurological and urological indications.
View full company profileAbout Exxel Pharma
Exxel Pharma is advancing a novel, peripherally-targeted therapeutic platform based on the inhibition of the fatty acid amide hydrolase (FAAH) enzyme to treat conditions driven by neuronal hypersensitivity. Its lead asset, EX937, is poised to enter Phase 1/1b trials for refractory chronic cough, a large market with no FDA-approved therapies. The company's strategy leverages a dual-program approach, with a second set of global FAAH inhibitors targeting central nervous system conditions like Social Anxiety Disorder and Autism Spectrum Disorder. Led by an experienced founder/CEO and a distinguished CSO, Exxel is positioned to address significant unmet needs across multiple high-value neurological and urological indications.
View full company profileTherapeutic Areas
Other Refractory Chronic Cough Drugs
| Drug | Company | Phase |
|---|---|---|
| Camlipixant (gefapixant) | GSK plc | Regulatory Review |